Stroke treatment economic model (STEM): Predicting long-term costs from functional status

Stroke

Volumn 30, Issue 12, 1999, Pages 2574-2579

  Caro, J Jaime ^a,b   Huybrechts, Krista F ^a  

^a Caro Research   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Costs and cost analysis; Stroke; Stroke outcome

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; HEALTH CARE COST; HEALTH STATUS; HOSPITALIZATION; HUMAN; LONG TERM CARE; MODEL; PRIORITY JOURNAL; STROKE;

EID: 0032710121     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.12.2574     Document Type: Article

References (28)

1. Galium R, Wilson J. The burden of stroke and its sequelae. Dis Manage Health Outcomes. 1997;1:84-94.
2. O'Brien JA, Caro JJ, Klittich WS. Beyond acute care: the true cost of stroke. Clin Ther. 1996;18(suppl A):21. Abstract.
3. The Brain at Risk: Understanding and Preventing Stroke. Englewood, Colo; National Stroke Association; 1996.
4. Wolfe C, Beech R, Ratcliffe M. Rudd AG. Stroke care in Europe: can we learn lessons from the different ways stroke is managed in different countries? J R Soc Health. 1995;115:143-147.
5. American Heart Association. Economic cost of cardiovascular diseases. URL:http://www.americanheart.org/scientific/HSstats98/10econom.html.
6. Caplan L. Stroke treatment: promising but still struggling. JAMA. 1998; 279:1304-1306.
7. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
8. Fisher M, Bogousslavsky J. Further evolution toward effective therapy for acute ischemic stroke. JAMA. 1998;279:1298-1303.
9. Drummond M, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care. 1991;7:591-573.
10. Caro JJ, O'Brien JA, Klittich W, Jackson J. The economic impact of warfarin prophylaxis in nonvalvular atrial fibrillation. Dis Manage Clin Outcomes. 1997;1:54-60.
11. Diener HC, for the European and Australian Lubeluzole Ischemic Stroke Study Group. Multinational randomized controlled trial of lubeluzole in acute ischemic stroke. Cerebrovasc Dis. 1998;8:172-181.
12. Grotta J, for the US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment of acute ischemic stroke. Stroke. 1997;28: 2338-2346.
13. Persson U, Silverberg R, Lindgren B, Norrving B, Jadbäck G, Johansson B, Puranen B-I. Direct costs of stroke for a Swedish population. Intl J Technol Assess Health Care. 1990;6:125-137.
14. Dennis M, Langhorne P. So stroke units save lives: where do we go from here? BMJ. 1994;309:1273-1277.
15. Beech R, Ratcliffe M, Tilling K, Wolfe C, for Participants of the European Study of Stroke Care. Hospital services for stroke care: a European perspective. Stroke. 1996;27:1958-1964.
16. Matchar DB, Samsa GP, Matthews JR, Ancukiewicz M, Parmigiani G, Hasselblad V, Wolf PA, D'Agostino RB, Lipscomb J. The Stroke Prevention Policy Model: linking evidence and clinical decisions. Ann Intern Med. 1997;127:704-711.
17. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke. 1994;25:1149-1156.
18. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP. Kwiatkowski TG, Frankel M, Brott TG, Walker MD, for the NINDS rt-PA Stroke Study Group. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology. 1998;50:883-890.
19. Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies: practical applications and methodological short-comings. Pharmacoeconomics. 1997;12:121-129.
20. Sonnenberg FA, Beck JR. Markov model in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
21. Thorngren M, Westling B. Rehabilitation and achieved health quality after stroke: A population-based study of 258 hospitalized cases followed for one year. Acta Neurol Scand. 1990;82:374-380.
22. Dennis MS, Burn JPS, Sandercock PAG, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796-800.
23. Mahoney FI, Barthel DW, Functional evaluation: the Barthel Index. Maryland Slate Med J. 1965;14:61-65.
24. Wilkinson PR, Wolfe CDA, Warburton FG, Rudd AG, Howard RS, Ross-Russell RW, Beech R. Longer term quality of life and outcome in stroke patients: is the Barthel Index alone an adequate measure of outcome? Qual Health Care. 1997;6:125-130.
25. Netten A, Dennett J. Unit Costs of Health and Social Care. Canterbury, UK: Personal Social Services Research Unit, University of Kent; 1996.
26. National Health Service. Scottish Health Service Costs. Edinburgh, Scotland: Information and Statistics Division, National Health Service; 1995.
27. Granger CV, Hamilton BB, Gresham GE, Kramer AA. The Stroke Rehabilitation Outcome Study, part II. Arch Phys Med Rehabil. 1989;70:100-103.
28. Mauthe RW, Haaf DC, Hayn P, Krall JM. Predicting discharge destination of stroke patients using a mathematical model based on six items from the functional independence measure. Arch Phys Med Rehabil. 1996;77:10-13.